Viking Therapeutics Faces Intensifying Competition in Obesity Drug Race

The obesity treatment market is becoming increasingly competitive as multiple pharmaceutical companies advance their GLP-1 receptor agonist candidates. Viking Therapeutics finds itself under significant investor scrutiny as the industry questions whether this biotechnology firm can effectively compete in this multi-billion dollar therapeutic area.

During the Morgan Stanley Global Healthcare Conference on September 8, CEO Brian Lian outlined the company’s strategic direction. Viking is concentrating resources on advancing its obesity treatments through late-stage clinical trials while simultaneously building robust manufacturing capabilities.

Key corporate strengths include:

• Substantial cash reserves: The company reported over $800 million in cash at the end of the second quarter, providing ample funding for its Phase III clinical program
• Advanced... Read more...